Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice

Japanese Journal of Cancer Research

Volumn 93, Issue 7, 2002, Pages 834-841

  Kimata, Masaru ^a   Otani, Yoshihide ^a   Kubota, Tetsuro ^a   Igarashi, Naoki ^a   Yokoyama, Takeyoshi ^a   Wada, Norihito ^a   Yoshimizu, Nobunari ^a   Fujii, Masato ^a   Kameyama, Kaori ^a   Okada, Yasunori ^a   Kumai, Koichiro ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Gastric cancer; Marimastat; MMP inhibitor; Peritoneal dissemination

Indexed keywords

ANTINEOPLASTIC AGENT; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MITOMYCIN C; ANTINEOPLASTIC ANTIBIOTIC; COLORING AGENT; ENZYME INHIBITOR; HYDROXAMIC ACID; MATRIX METALLOPROTEINASE; MITOMYCIN; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; INOCULATION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PERITONEUM METASTASIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STOMACH CARCINOMA; SURVIVAL TIME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BODY WEIGHT; CANCER TRANSPLANTATION; CELL CULTURE; CELL SURVIVAL; CHEMICAL MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; METASTASIS; PATHOLOGY; PERITONEUM; STOMACH TUMOR; TIME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CELL SURVIVAL; COLORING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOMYCIN; MODELS, CHEMICAL; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PERITONEUM; STOMACH NEOPLASMS; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036048505     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2002.tb01326.x     Document Type: Article

References (34)

1. Cancer metastasis and angiogenesis; an imbalance of positive and negative regulation
2. Marimastat (BB2516): Current status of development
3. Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-I in nude mice
4. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastasis in mice bearing Lewis lung carcinoma
5. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma zenografts
6. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by matrix metalloproteinase inhibitor batimastat
7. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340
8. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
9. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
10. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: A phase I AIDS Malignancy Consortium study
11. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on Batimastat and Marimastat
12. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies
13. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers
14. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial
15. An immunohistochemical study of human gastric carcinoma in nude mice and athymic rats with special reference to secretory component production
16. Growth-promoting effect of gastrin on human gastric carcinoma cell line TMK-1
17. Development of 3T3-like lines from Balb-c mouse embryo cultures: Transformation susceptibility to SV40
18. Matrix metalloproteinase inhibitors
19. Rapid calorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
20. MTT assay with reference to clinical effect of chemotherapy
21. Clinical usefulness of chemotherapy testing using the MTT assay
22. Gene expression of interstitial collagenase (matrix metalloproteinase 1) in gastrointestinal tract cancers
23. Expression of interstitial collagenase (matrix metalloproteinase-1) in gastric cancers
24. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components
25. Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer
26. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma
27. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
28. Ras-transfection up-regulated HaCaT cell migration inhibition by Marimastat
29. Marimastat inhibits neointimal thickening in a model of human arterial intimal hyperplasia
30. Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis
31. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models
32. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases
33. The citrus flavonoid, nobiletin, inhibits peritoneal dissemination of human gastric carcinoma in SCID mice
34. Inhibitory effect of citrus nobiletin on phorbol ester-induced skin inflammation, oxidative stress, and tumor promotion in mice